» Articles » PMID: 39148970

Mini Review Advantages and Limitations of Lytic Phages Compared with Chemical Antibiotics to Combat Bacterial Infections

Overview
Journal Heliyon
Specialty Social Sciences
Date 2024 Aug 16
PMID 39148970
Authors
Affiliations
Soon will be listed here.
Abstract

The overuse of antibiotics has caused the emergence of antibiotic-resistant strains, such as multidrug-resistant, extensively drug-resistant, and pandrug-resistant bacteria. The treatment of infections caused by such strains has become a formidable challenge. In the post-antibiotic era, phage therapy is an attractive solution for this problem and some successful phase 1 and 2 studies have demonstrated the efficacy and safety of phage therapy over the last decade. It is a form of evolutionary medicine, phages exhibit immunomodulatory and anti-inflammatory properties. However, phage therapy is limited by factors, such as the narrow spectrum of host strains, the special pharmacokinetics and pharmacodynamics , immune responses, and the development of phage resistance. The aim of this minireview was to compare the potencies of lytic phages and chemical antibiotics to treat bacterial infections. The advantages of phage therapy has fewer side effects, self-replication, evolution, bacterial biofilms eradication, immunomodulatory and anti-inflammatory properties compared with chemical antibiotics. Meanwhile, the disadvantages of phage therapy include the narrow spectrum of available host strains, the special pharmacokinetics and pharmacodynamics , immune responses, and phage resistance hurdles. Recently, some researchers continue to make efforts to overcome these limitations of phage therapy. Phage therapy will be a welcome addition to the gamut of options available for treating antibiotic-resistant bacterial infections. We focus on the advantages and limitations of phage therapy with the intention of exploiting the advantages and overcoming the limitations.

Citing Articles

Two virulent Vibrio campbellii phages with potential for phage therapy in aquaculture.

Ding H, Shi K, Hsiao M, Li W, Liu X, Xu J BMC Microbiol. 2025; 25(1):99.

PMID: 40021993 PMC: 11869677. DOI: 10.1186/s12866-025-03803-0.


A theoretical exploration of protocols for treating prosthetic joint infections with combinations of antibiotics and bacteriophage.

Levin B, Gil-Gil T, Berryhill B, Woodworth M bioRxiv. 2025; .

PMID: 39990355 PMC: 11844561. DOI: 10.1101/2025.02.16.638499.


Current Knowledge on CRISPR Strategies Against Antimicrobial-Resistant Bacteria.

de la Fuente Tagarro C, Martin-Gonzalez D, De Lucas A, Bordel S, Santos-Beneit F Antibiotics (Basel). 2025; 13(12.

PMID: 39766530 PMC: 11672446. DOI: 10.3390/antibiotics13121141.


Comprehensive Approaches to Combatting Biofilms: From Biofilm Structure to Phage-Based Therapies.

Grygiel I, Bajrak O, Wojcicki M, Krusiec K, Jonczyk-Matysiak E, Gorski A Antibiotics (Basel). 2024; 13(11).

PMID: 39596757 PMC: 11591314. DOI: 10.3390/antibiotics13111064.

References
1.
Chabas H, van Houte S, Hoyland-Kroghsbo N, Buckling A, Westra E . Immigration of susceptible hosts triggers the evolution of alternative parasite defence strategies. Proc Biol Sci. 2016; 283(1837). PMC: 5013786. DOI: 10.1098/rspb.2016.0721. View

2.
Merabishvili M, Pirnay J, Verbeken G, Chanishvili N, Tediashvili M, Lashkhi N . Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials. PLoS One. 2009; 4(3):e4944. PMC: 2654153. DOI: 10.1371/journal.pone.0004944. View

3.
Anand T, Virmani N, Kumar S, Mohanty A, Pavulraj S, Bera B . Phage therapy for treatment of virulent Klebsiella pneumoniae infection in a mouse model. J Glob Antimicrob Resist. 2019; 21:34-41. DOI: 10.1016/j.jgar.2019.09.018. View

4.
Guo Z, Huang J, Yan G, Lei L, Wang S, Yu L . Identification and Characterization of Dpo42, a Novel Depolymerase Derived from the Phage vB_EcoM_ECOO78. Front Microbiol. 2017; 8:1460. PMC: 5539073. DOI: 10.3389/fmicb.2017.01460. View

5.
Guo Z, Lin H, Ji X, Yan G, Lei L, Han W . Therapeutic applications of lytic phages in human medicine. Microb Pathog. 2020; 142:104048. DOI: 10.1016/j.micpath.2020.104048. View